A 39-year-old woman (Case 1) and a 57-year-old woman (Case 2) underwent allogeneic bone marrow transplantation for acute lymphoblastic leukemia and follicular lymphoma, respectively. Both patients had received tacrolimus orally for treatment of or prophylaxis against graft-versus-host disease. Seventeen months (Case 1) and 2 months (Case 2) post-transplantation, when the trough level of tacrolimus was maintained around 10 ng/ml, the serum sodium levels of Cases 1 and 2 decreased to 123.5 mEq/l and 125.6 mEq/l, respectively. Urinary sodium excretions increased to 186.8 mEq/day and 375.7 mEq/day, respectively. Sodium-losing nephropathy due to tacrolimus was diagnosed, and reducing the dose of tacrolimus with no other intervention resulted in resolution of the hyponatremia. Although sporadic kidney transplantation cases with sodium-losing nephropathy due to tacrolimus have been reported, no prior cases with this complication after hematopoietic stem cell transplantation (HSCT) have been reported. Sodium-losing nephropathy should be recognized as one of the renal toxicities of tacrolimus in HSCT as well as kidney recipients.
|Number of pages||5|
|Publication status||Published - 2013 Dec|
ASJC Scopus subject areas